<DOC>
	<DOCNO>NCT01868516</DOCNO>
	<brief_summary>Overactive bladder ( OAB ) syndrome characterize symptom sudden need urinate without incontinence ( leak ) . The purpose study test whether dexmecamylamine safe effective compare placebo treatment symptom OAB .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability , Efficacy Dexmecamylamine ( TC-5214 ) Treatment Overactive Bladder</brief_title>
	<detailed_description>The study include three- five-week screening period , follow 12-week treatment period patient receive either one three dos dexmecamylamine placebo twice daily , randomize ratio 2:1:1:1 ( placebo , low dose , mid dose , high dose ) , two-week follow-up period . A total 768 subject overactive bladder randomize double-blind treatment period study .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>Verified medical history overactive bladder least 6 month Capable walk unassisted use bathroom Able measure void urine volume complete diary without assistance If subject currently treat OAB medication , subject willing discontinue OAB medication participate study Diagnosis neurological disease affect bladder function Stress incontinence , insensate incontinence , overflow incontinence incontinence due urinary fistula History incomplete bladder emptying , bladder outflow obstruction postvoid residual bladder volume &gt; 150 mL Males benign prostatic hyperplasia prostatespecific antigen ( PSA ) 4 ng/mL Other urinary tract pathology malignancy , ureteric reflux , bladder stone , uninvestigated hematuria , urethral stricture , cystitis Prior treatment intravesical intraprostatic botulinum toxin last 2 year Myasthenia gravis Angle closure glaucoma Current implantation interstim electrodes vaginal surgical mesh Presence clinically significant medical condition time study Presence clinically significant abnormality laboratory finding , physical exam finding vital sign Participated investigational drug trial within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>